HMPL-653
Tenosynovial Giant Cell Tumor
Phase 2Active
Key Facts
About HUTCHMED
HUTCHMED is a leading, innovation-driven biopharma focused on oncology and immunology, with a strategy of 'in China, for the world.' The company has successfully brought novel drugs like fruquintinib (ELUNATE®) to market in China and achieved its first global approval with Takeda. Its business model integrates discovery, development, manufacturing, and commercialization, supported by a deep pipeline of both internally discovered and in-licensed assets. HUTCHMED aims to become a global biopharmaceutical leader by advancing its pipeline through strategic global partnerships.
View full company profileTherapeutic Areas
Other Tenosynovial Giant Cell Tumor Drugs
| Drug | Company | Phase |
|---|---|---|
| TURALIO (pexidartinib) | Daiichi Sankyo | Approved |